Welcome to our dedicated page for RAPT Therapeutics SEC filings (Ticker: RAPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RAPT Therapeutics, Inc. filings document the regulatory record of a clinical-stage immunology biopharmaceutical company and its transition from a Nasdaq-listed issuer to a wholly owned subsidiary of GlaxoSmithKline LLC. The record includes Form 8-K disclosures for operating and financial results, Regulation FD presentation materials, material agreements, capital-structure matters, and shareholder-related transaction disclosures.
Later filings include a Form 25 for removal of RAPT common stock from Nasdaq listing and registration, and a Form 15 covering termination of registration or suspension of reporting duties for its common stock. These documents record the completed merger, the surviving-company structure, the delisting process, and Exchange Act reporting-status changes.
RAPT Therapeutics director Linda Kozick reported the disposition of stock options and common shares in connection with the company’s acquisition by a GlaxoSmithKline affiliate. Multiple “Director Stock Option (right to buy)” awards were disposed of to the issuer on March 3, 2026, leaving no options reported as outstanding afterward.
Under a January 19, 2026 Merger Agreement, a GSK subsidiary completed a tender offer for all RAPT shares at $58.00 per share in cash and then merged into RAPT. The filing notes that RSUs and stock options were cancelled at the merger effective time and converted into cash based on the offer price where in-the-money, while out-of-the-money options were cancelled without payment. The Form 4 also shows a tender-offer disposition of 4,956 shares of common stock for cash consideration at the offer price.
RAPT Therapeutics director Scott Braunstein reported dispositions of equity tied to the company’s merger with a GlaxoSmithKline affiliate. He surrendered 25,000 director stock options back to the issuer and disposed of 4,956 common shares through a tender offer at $58.00 per share.
The filing explains that, under the Merger Agreement, outstanding restricted stock units and stock options were cancelled at the merger’s effective time and converted into cash based on the $58.00 offer price. These transactions reflect automatic treatment of director awards in connection with RAPT becoming an indirect wholly owned subsidiary of GlaxoSmithKline LLC.
RAPT Therapeutics, Inc. files post-effective amendments to deregister all unsold securities under Registration Statements No. 333-273910 and No. 333-284388 after the closing of a merger.
The amendments state that pursuant to the Agreement and Plan of Merger dated January 19, 2026, effective March 3, 2026, RAPT merged into a GlaxoSmithKline affiliate and is now a wholly owned subsidiary; offerings under those registration statements have been terminated and the unsold securities removed from registration.
RAPT Therapeutics has filed post-effective amendments to its Form S-3 registration statements Registration No. 333-273910 and Registration No. 333-284388 to deregister any securities that remained unsold as of March 3, 2026. The company states that, pursuant to the Agreement and Plan of Merger dated January 19, 2026, Merger Sub merged with and into the registrant and the registrant became a wholly owned subsidiary of GlaxoSmithKline LLC. As a result, the registrant terminated offerings under those registration statements and removed all unsold securities from registration, so there will be no remaining securities registered under those registration statements.
RAPT Therapeutics, Inc. notified Nasdaq Stock Market LLC of the voluntary removal of its Common Stock from listing and registration.
The notification states Nasdaq and the issuer each complied with the applicable rules under 17 CFR 240.12d2-2 governing withdrawal and delisting; the filing is signed by a Nasdaq representative.
RAPT Therapeutics, Inc. has been acquired by GlaxoSmithKline through a cash tender offer followed by a merger under Delaware law. GSK’s subsidiary purchased all outstanding RAPT common shares at $58.00 per share in cash, and approximately 30,137,567 shares, or 93.36% of outstanding shares, were validly tendered.
After completing the offer, GSK merged its acquisition vehicle into RAPT, making RAPT a direct wholly owned subsidiary. RAPT’s Nasdaq-listed common stock will be halted, delisted and deregistered, and the company plans to terminate its SEC reporting obligations. RAPT’s prior directors and officers resigned, and new GSK-affiliated officers and directors were appointed.
RAPT Therapeutics filed Amendment No. 2 to its Schedule 14D-9 reporting final results of the tender offer by an affiliate of GSK. The Offer at $58.00 per share expired on March 2, 2026, with 30,137,567 Shares validly tendered, representing 93.36% of issued and outstanding Shares as of the Expiration Time. The filing states the Minimum Condition was satisfied, Purchaser accepted for payment the Shares, and the Company expects Parent to complete the merger on March 3, 2026, after which the Shares will be delisted and registration and reporting under the Exchange Act will be terminated.
RAPT Therapeutics was acquired via a completed tender offer by Redrose Acquisition Co., GlaxoSmithKline LLC and GSK plc for $58.00 per share. The offer expired at one minute after 11:59 P.M. Eastern on March 2, 2026, and 30,137,567 Shares were validly tendered, representing 93.36% of issued and outstanding Shares as of that time.
Because the Minimum Condition was satisfied, Purchaser accepted the tendered Shares and will pay for them promptly. Under Section 251(h) of the DGCL, Ultimate Parent, Parent and Purchaser intend to effect the Merger without a stockholder meeting, delist the Shares from Nasdaq, and take steps to terminate registration and suspend reporting as promptly as practicable.